Allogeneic T Cell Therapies Global Market Report 2024

Description

Allogeneic T cell therapies represent an advanced medical approach where T cells, critical to the immune system, are sourced from a donor and utilized to attack cancer cells in a recipient. These therapies are primarily applied in the treatment of challenging cancers that are resistant to conventional therapies.

The key forms of allogeneic T cell therapies include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. CAR T-cell therapies are a type of immunotherapy where T-cells are genetically engineered to target and eliminate cancer cells by recognizing specific proteins on them. Targeted antigens in these therapies include CD19, CD20, EgfrvIII, GD2, CD22, CD30, CD33, Meso, HER1, among others. These therapies address various conditions such as cancer, autoimmune disorders, and infectious diseases, with applications spanning hospitals, specialty clinics, research institutions, and other healthcare facilities.

The allogeneic T cell therapies market research report is one of a series of new reports from The Business Research Company that provides allogeneic T cell therapies market statistics, including the allogeneic T cell therapies industry's global market size, regional shares, competitors with an allogeneic T cell therapies market share, detailed allogeneic T cell therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the allogeneic T cell therapies industry. This allogeneic T cell therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allogeneic T cell therapies market size has grown strongly in recent years. It will grow from $1.06 billion in 2023 to $1.16 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historical period can be attributed to key factors such as regulatory approvals, a rising incidence of cancer, an increase in clinical trials, government funding, and an expanding geriatric population.

The allogeneic T cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period is expected to be driven by expanding treatment indications, increased demand for cell-based immunotherapies, heightened awareness of advanced therapies, rising healthcare expenditures, and favorable reimbursement policies. Key trends anticipated in this period include advancements in research and development, the rise of personalized medicine, the development of off-the-shelf therapies, global market expansion, strategic partnerships, and changes in the regulatory landscape.

The growing incidence of cancer is expected to drive the expansion of the allogeneic T cell therapies market. Cancer is a group of diseases marked by the uncontrolled proliferation and spread of abnormal cells in the body. The rise in cancer cases is linked to factors such as increased life expectancy, lifestyle changes, environmental exposures, infections, genetic predispositions, and shifts in reproductive patterns, all of which contribute to a higher incidence and detection of cancer. Allogeneic T cell therapies, which involve infusing genetically engineered donor T cells to target and destroy cancer cells, are increasingly being used in cancer treatment. According to the National Cancer Institute in May 2024, there were approximately 18.1 million cancer survivors in the U.S., a number projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths rising to 15.3 million. These trends are expected to propel the growth of the allogeneic T cell therapies market.

Leading companies in the allogeneic T cell therapies market are focusing on developing innovative chimeric antigen receptor (CAR) T-cell therapy programs to enhance treatment effectiveness and broaden therapeutic options. These advanced initiatives aim to improve the efficiency, accessibility, and delivery of CAR T-cell therapies for cancer. For example, in October 2022, Allogene Therapeutics Inc., a U.S.-based biotechnology company, launched CAR T Together, an initiative aimed at addressing challenges related to the delivery and accessibility of CAR T therapies. The program seeks to streamline clinical trial enrollment and foster collaboration among oncologists to expedite the development of allogeneic CAR T therapies. Unlike autologous therapies, which use a patient's own cells, allogeneic therapies rely on T cells from healthy donors, allowing for more efficient manufacturing processes.

In January 2023, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for an undisclosed sum. This acquisition is part of AstraZeneca's strategy to advance innovative treatments and bolster its oncology capabilities, particularly in developing therapies for solid tumors that target cancer-specific mutations. Neogene Therapeutics Inc. is a U.S.-based biotechnology firm specializing in allogeneic T cell therapies.

Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc, Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc, Bellicum Pharmaceuticals Inc.

North America was the largest region in the allogeneic T cell therapies market in 2023. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allogeneic t cell therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allogeneic T cell therapies market includes revenues earned by entities providing services such as allogeneic CAR-t cell therapy, allogeneic TCR-t cell therapy, allogeneic NK or T cell therapy, off-the-shelf allogeneic t cell therapy, allogeneic virus-specific t cell therapy, and universal donor t cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allogeneic T Cell Therapies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on allogeneic T cell therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allogeneic T cell therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The allogeneic T cell therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies; T Cell Receptor (TCR) Therapies; Other Product Types
2) By Antigen Type: CD 19; CD 20; Egfrvlll; GD2; CD22; CD30; CD33; Meso; HER1; Other Antigen Types
3) By Therapeutics Indications: Cancer; Autoimmune Diseases; Infectious Diseases; Others Therapeutics Indications
4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Gilead Sciences Inc.; Immatics NV; Sangamo Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r20126

1. Executive Summary

2. Allogeneic T Cell Therapies Market Characteristics

3. Allogeneic T Cell Therapies Market Trends And Strategies

4. Allogeneic T Cell Therapies Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Allogeneic T Cell Therapies Market Size and Growth

5.1. Global Allogeneic T Cell Therapies Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Allogeneic T Cell Therapies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Allogeneic T Cell Therapies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Allogeneic T Cell Therapies Market Segmentation

6.1. Global Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Chimeric Antigen Receptor (CAR) T Cell Therapies
T Cell Receptor (TCR) Therapies
Other Product Types
6.2. Global Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
CD 19
CD 20
Egfrvlll
GD2
CD22
CD30
CD33
Meso
HER1
Other Antigen Types
6.3. Global Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Cancer
Autoimmune Diseases
Infectious Diseases
Others Therapeutics Indications
6.4. Global Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Research Institutes
Other End-Users

7. Allogeneic T Cell Therapies Market Regional And Country Analysis

7.1. Global Allogeneic T Cell Therapies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Allogeneic T Cell Therapies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Allogeneic T Cell Therapies Market

8.1. Asia-Pacific Allogeneic T Cell Therapies Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Allogeneic T Cell Therapies Market

9.1. China Allogeneic T Cell Therapies Market Overview
9.2. China Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Allogeneic T Cell Therapies Market

10.1. India Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Allogeneic T Cell Therapies Market

11.1. Japan Allogeneic T Cell Therapies Market Overview
11.2. Japan Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Allogeneic T Cell Therapies Market

12.1. Australia Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Allogeneic T Cell Therapies Market

13.1. Indonesia Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Allogeneic T Cell Therapies Market

14.1. South Korea Allogeneic T Cell Therapies Market Overview
14.2. South Korea Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Allogeneic T Cell Therapies Market

15.1. Western Europe Allogeneic T Cell Therapies Market Overview
15.2. Western Europe Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Allogeneic T Cell Therapies Market

16.1. UK Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Allogeneic T Cell Therapies Market

17.1. Germany Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Allogeneic T Cell Therapies Market

18.1. France Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Allogeneic T Cell Therapies Market

19.1. Italy Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Allogeneic T Cell Therapies Market

20.1. Spain Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Allogeneic T Cell Therapies Market

21.1. Eastern Europe Allogeneic T Cell Therapies Market Overview
21.2. Eastern Europe Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Allogeneic T Cell Therapies Market

22.1. Russia Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Allogeneic T Cell Therapies Market

23.1. North America Allogeneic T Cell Therapies Market Overview
23.2. North America Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Allogeneic T Cell Therapies Market

24.1. USA Allogeneic T Cell Therapies Market Overview
24.2. USA Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Allogeneic T Cell Therapies Market

25.1. Canada Allogeneic T Cell Therapies Market Overview
25.2. Canada Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Allogeneic T Cell Therapies Market

26.1. South America Allogeneic T Cell Therapies Market Overview
26.2. South America Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Allogeneic T Cell Therapies Market

27.1. Brazil Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Allogeneic T Cell Therapies Market

28.1. Middle East Allogeneic T Cell Therapies Market Overview
28.2. Middle East Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Allogeneic T Cell Therapies Market

29.1. Africa Allogeneic T Cell Therapies Market Overview
29.2. Africa Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Allogeneic T Cell Therapies Market Competitive Landscape And Company Profiles

30.1. Allogeneic T Cell Therapies Market Competitive Landscape
30.2. Allogeneic T Cell Therapies Market Company Profiles
- 30.2.1. Bristol-Myers Squibb Company
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novartis AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Gilead Sciences Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Immatics NV
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Sangamo Therapeutics Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Allogeneic T Cell Therapies Market Other Major And Innovative Companies

31.1. Poseida Therapeutics Inc.
31.2. Fate Therapeutics Inc.
31.3. Atara Biotherapeutics Inc.
31.4. Sorrento Therapeutics Inc
31.5. Autolus Therapeutics Plc
31.6. MaxCyte Inc.
31.7. Tessa Therapeutics Pte Ltd.
31.8. Cell Medica Inc.
31.9. Enlivex Therapeutics Ltd.
31.10. Cellectis SA
31.11. Adaptimmune Therapeutics Plc
31.12. Medigene AG
31.13. Celyad Oncology SA
31.14. Allogene Therapeutics Inc
31.15. Bellicum Pharmaceuticals Inc.

32. Global Allogeneic T Cell Therapies Market Competitive Benchmarking

33. Global Allogeneic T Cell Therapies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Allogeneic T Cell Therapies Market

35. Allogeneic T Cell Therapies Market Future Outlook and Potential Analysis

35.1 Allogeneic T Cell Therapies Market In 2028 - Countries Offering Most New Opportunities
35.2 Allogeneic T Cell Therapies Market In 2028 - Segments Offering Most New Opportunities
35.3 Allogeneic T Cell Therapies Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer